New eye drug targets fluid buildup to fight glaucoma
NCT ID NCT07675824
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests an experimental drug called REGN22530 in people with primary open angle glaucoma or ocular hypertension. The drug is designed to block a protein in the eye that causes fluid buildup and high pressure. Researchers are checking for side effects, how the drug moves through the body, and whether it lowers eye pressure effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN22530
What this could lead to
If successful, this drug could offer a new way to lower eye pressure and help control glaucoma or ocular hypertension, potentially reducing the need for daily eye drops.
What could go wrong
This is an early-phase trial, so the drug may not work as expected or could cause side effects. It is not a cure, and long-term safety and effectiveness are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY OPEN ANGLE GLAUCOMA (POAG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••